

# Yondelis® (trabectedin) (Intravenous)

Document Number: IC-0257

**Last Review Date: 09/04/2025**

**Date of Origin: 12/04/2015**

**Dates Reviewed: 12/2015, 07/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 12/2020, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 12/2022, 03/2023, 06/2023, 09/2023, 12/2023, 03/2024, 09/2025**

## I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 6 months.
- Renewal: Prior authorization validity may be renewed every 6 months thereafter.

## II. Dosing Limits

**Max Units (per dose and over time) [HCPCS Unit]:**

- All Indications: 40 billable units every 21 days

## III. Initial Approval Criteria <sup>1</sup>

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

**Universal Criteria <sup>1</sup>**

- Left ventricular ejection fraction (LVEF) is within normal limits prior to initiating therapy and will be assessed at regular intervals (e.g., every 3 months) during treatment; **AND**

**Soft Tissue Sarcoma (STS) ‡ <sup>1-4,8-11</sup>**

- Used in combination with doxorubicin; **AND**
  - Patient has leiomyosarcoma; **AND**
    - Used as first-line therapy; **AND**
      - Patient has advanced, metastatic, unresectable, or recurrent disease of the extremity/body wall/head-neck; **OR**
      - Patient has advanced, metastatic, unresectable, or residual disease (R2 resection) of the retroperitoneal or intra-abdominal area; **OR**
    - Used as alternative systemic therapy for unresectable or progressive disease of the retroperitoneal or intra-abdominal area after receiving initial therapy for unresectable localized disease; **OR**
    - Used as subsequent palliative therapy for advanced or metastatic disease; **AND**
      - Patient has retroperitoneal/intra-abdominal\*\* STS; **OR**

- Patient has extremity/body wall, head/neck\* STS; **OR**
- Used as single agent therapy; **AND**
  - Patient has liposarcoma or leiomyosarcoma † Φ; **AND**
    - Used for unresectable or metastatic disease after an anthracycline-containing regimen (e.g., doxorubicin, liposomal doxorubicin, epirubicin, etc.); **OR**
  - Used as palliative therapy for solitary fibrous tumor; **OR**
  - Patient has dedifferentiated liposarcoma with or without concurrent well-differentiated liposarcoma; **OR**
  - Patient has epithelioid hemangioendothelioma; **OR**
  - Used as neoadjuvant therapy; **AND**
    - Patient has myxoid liposarcoma; **AND**
      - Extremity/Body Wall, Head/Neck; **AND**
        - Used for stage III or stage IV (any T, N1, M0) resectable disease with acceptable functional outcomes; **OR**
      - Retroperitoneal/Intra-Abdominal; **AND**
        - Used for resectable primary or recurrent localized disease at high risk of becoming metastatic OR if downstaging is needed to facilitate resection (*Note: Systemic therapy is not recommended for low-grade tumors*); **OR**
        - Used for unfavorable tumor biology for stage IV disease with single organ and limited tumor bulk that are amenable to local therapy; **OR**
  - Used as adjuvant therapy; **AND**
    - Patient has myxoid liposarcoma; **AND**
      - Extremity/Body Wall, Head/Neck; **AND**
        - Patient has stage III or stage IV (any T, N1, M0) resectable disease with acceptable functional outcomes; **OR**
        - Patient has stage II, III, or stage IV (any T, N1, M0) resectable disease with unacceptable functional outcomes; **OR**
        - Patient has unresectable primary disease; **OR**
      - Retroperitoneal/Intra-Abdominal; **AND**
        - Used for disease at high risk of becoming metastatic (*Note: Systemic therapy is not recommended for low-grade tumors*); **OR**
  - Used as primary treatment; **AND**
    - Patient has myxoid liposarcoma; **AND**
      - Extremity/Body Wall, Head/Neck; **AND**
        - Patient has synchronous stage IV disease with single organ disease (primarily pulmonary) or oligometastatic disease, with limited tumor bulk that is amenable to local therapy; **OR**

- Patient has stage II, III, or IV (any T, N1, M0) resectable disease with unacceptable functional outcomes; **OR**
- Patient has unresectable disease; **OR**
- o Used as subsequent palliative therapy; **AND**
  - Rhabdomyosarcoma; **AND**
    - Used for advanced or metastatic pleomorphic rhabdomyosarcoma; **OR**
  - Retroperitoneal/Intra-Abdominal\*\*; **AND**
    - Used for stage IV disease with disseminated metastases; **OR**
    - Used as alternative systemic therapy for unresectable or progressive disease after receiving initial therapy for unresectable localized disease; **OR**
  - Extremity/Body Wall, Head/Neck\*; **AND**
    - Used for advanced or metastatic disease with disseminated metastases

*\* For atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS) of the extremity, abdominal wall, trunk that was initially diagnosed as ALT/WDLPS and shows evidence of de-differentiation, treat as other soft tissue sarcomas.*

*\*\* For well-differentiated liposarcoma (WDLPS-retroperitoneum, paratesticular) with or without evidence of de-differentiation, treat as other soft tissue sarcomas*

#### **Uterine Sarcoma ‡<sup>2,5,8</sup>**

- Patient has uterine leiomyosarcoma (uLMS); **AND**
- Patient has advanced, recurrent/metastatic, or inoperable disease; **AND**
  - o Used as subsequent therapy; **AND**
    - Used as a single agent therapy; **OR**
  - o Used as first-line therapy or subsequent therapy (if not previously used); **AND**
    - Used in combination doxorubicin

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

## **IV. Renewal Criteria<sup>1</sup>**

Prior authorization validity may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cardiomyopathy, rhabdomyolysis, hepatotoxicity and/or severe hepatic impairment, capillary leak syndrome (CLS), severe neutropenia/neutropenic sepsis, extravasation resulting in tissue necrosis, etc.; **AND**

- Left ventricular ejection fraction (LVEF) has not had an absolute decrease of  $\geq 15\%$  from baseline OR is not below the lower limit of normal (LLN) with an absolute decrease of  $\geq 5\%$  (LVEF results must be within the previous 3 months)

## V. Dosage/Administration <sup>1,6-9</sup>

Indication	Dose
Soft Tissue Sarcoma	<p><b><u>Single agent therapy</u></b> Administer 1.5 mg/m<sup>2</sup> intravenously every 21 days, until disease progression or unacceptable toxicity</p> <p><b><u>Single agent therapy (myxoid liposarcoma)</u></b> Administer 1.3 mg/m<sup>2</sup> intravenously every 21 days, until disease progression or unacceptable toxicity</p> <p><b><u>In combination with doxorubicin (leiomyosarcoma ONLY as first-line, alternative systemic therapy, or subsequent palliative therapy)</u></b> Administer 1.1 mg/m<sup>2</sup> intravenously, with doxorubicin, every 21 days for up to 6 cycles, followed by single agent maintenance treatment at a dose of 1.1 mg/m<sup>2</sup> every 21 days until disease progression or unacceptable toxicity</p>
Uterine Sarcoma	<p><b><u>In combination with doxorubicin (first-line or subsequent therapy)</u></b> Administer 1.1 mg/m<sup>2</sup> intravenously, with doxorubicin, every 21 days for up to 6 cycles, followed by single agent maintenance treatment at a dose of 1.1 mg/m<sup>2</sup> every 21 days until disease progression or unacceptable toxicity</p> <p><b><u>Single agent therapy (subsequent therapy)</u></b> Administer 1.5 mg/m<sup>2</sup> intravenously every 21 days, until disease progression or unacceptable toxicity</p>

## VI. Billing Code/Availability Information

### HCPCS Code:

- J9352 – Injection, trabectedin, 0.1 mg; 1 billable unit = 0.1 mg

### NDC:

- Yondelis 1 mg single-dose vial for injection: 59676-0610-xx

## VII. References

1. Yondelis [package insert]. Horsham, PA; Janssen Products, LP; June 2020. Accessed August 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium<sup>®</sup>) trabectedin. National Comprehensive Cancer Network, 2025. The NCCN Compendium<sup>®</sup> is a derivative work of the NCCN Guidelines<sup>®</sup>. NATIONAL COMPREHENSIVE

CANCER NETWORK<sup>®</sup>, NCCN<sup>®</sup>, and NCCN GUIDELINES<sup>®</sup> are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2025.

3. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. *J Clin Oncol*. 2016;34(8):786-793.
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Soft Tissue Sarcoma, Version 1.2025. National Comprehensive Cancer Network, 2025. NATIONAL COMPREHENSIVE CANCER NETWORK<sup>®</sup>, NCCN<sup>®</sup>, and NCCN GUIDELINES<sup>®</sup> are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2025.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Uterine Neoplasms, Version 3.2025. National Comprehensive Cancer Network, 2025. NATIONAL COMPREHENSIVE CANCER NETWORK<sup>®</sup>, NCCN<sup>®</sup>, and NCCN GUIDELINES<sup>®</sup> are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed August 2025
6. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol*. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9.
7. Hensley ML, Patel SR, von Mehren M, et al. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *Gynecol Oncol*. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018.
8. Pautier P, Italiano A, Neumann S, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. *Lancet Oncol*. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.
9. Pautier P, Floquet A, Chevreau C, et al. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. *ESMO Open*. 2021 Aug;6(4):100209. doi: 10.1016/j.esmoop.2021.100209. Epub 2021 Jul 26.
10. Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. *Lancet Oncol*. 2015 Apr;16(4):406-16. doi: 10.1016/S1470-2045(15)70098-7. Epub 2015 Mar 18. PMID: 25795406.
11. Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded

## Appendix A – Non-Quantitative Treatment Limitations (NQL) Factor Checklist

Non-quantitative treatment limitations (NQLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.3	Malignant neoplasm of peripheral nerves of thorax
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum

ICD-10	ICD-10 Description
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue
Z85.42	Personal history of malignant neoplasm of other parts of uterus
Z85.831	Personal history of malignant neoplasm of soft tissue

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

## Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC